// App-Quantinova.ai

936 : Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes

Researchers

Presenter

  • Lianne Gensler

Principal Investigators

  • Atul Deodhar

  • Walter P. Maksymowych

  • Nigil Haroon

  • Simone Auteri

  • Natasha de Peyrecave

  • Thomas Kumke

  • Bengt Hoepken

  • Lars Bauer

  • Martin Rudwaleit

Medical Centers

  • University of Massachusetts Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

  • University of California, San Francisco, CA

  • Oregon Health and Science University, Portland, OR

  • University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada

  • Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, Canada

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Monheim, Germany

  • UCB Pharma, Monheim am Rhein, Germany

  • Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany

Locations

  • United States

  • Canada

  • Belgium

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved